Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 3. Annual reported cases of notifiable diseases, by month*, United States, excluding U.S. Territories and Non-U.S. Residents, 2022
Disease Jan. Feb. Mar. Apr. May June July Aug. Sept. Oct. Nov. Dec. Unknown Total
Anthrax — — — — — — — — — — — — — —
Arboviral diseases
Chikungunya virus disease 7 3 7 4 1 6 7 10 9 13 5 9 — 81
Eastern equine encephalitis virus disease
Neuroinvasive — — — — — — — 1 — — — — — 1
Non-neuroinvasive — — — — — — — — — — — — — —
Jamestown Canyon virus disease
Neuroinvasive — — — — 1 2 1 2 1 3 1 — — 11
Non-neuroinvasive — — — 1 — — — — — — — — — 1
La Crosse virus disease
Neuroinvasive — — — — — — 6 4 7 1 1 — — 19
Non-neuroinvasive — — — — — — 1 — 1 1 — — — 3
Powassan virus disease
Neuroinvasive — 1 1 2 5 8 10 3 1 3 7 1 — 42
Non-neuroinvasive — — — 1 1 — — — — 2 — — — 4
St. Louis encephalitis virus disease
Neuroinvasive — 1 — — — 4 3 5 4 5 4 2 — 28
Non-neuroinvasive — — — — — — — 2 2 — 2 — — 6
West Nile virus disease
Neuroinvasive 4 2 — 2 3 12 67 253 304 145 21 15 — 828
Non-neuroinvasive 2 2 3 2 4 6 29 109 104 39 8 2 — 310
Western equine encephalitis virus disease
Neuroinvasive — — — — — — — — — — — — — —
Non-neuroinvasive — — — — — — — — — — — — — —
Babesiosis
Total 9 16 18 39 62 227 838 412 204 132 82 72 — 2,111
Confirmed 6 9 13 28 49 195 754 377 176 87 64 54 — 1,812
Probable 3 7 5 11 13 32 84 35 28 45 18 18 — 299
Botulism
Total 15 12 8 21 12 19 21 19 27 11 16 16 — 197
Foodborne 1 — — — 1 2 — 1 1 — — — — 6
Infant 13 11 8 19 10 15 17 16 18 7 15 14 — 163
Other (wound & unspecified) 1 1 — 2 1 2 4 2 8 4 1 2 — 28
Brucellosis 11 4 9 12 14 12 20 8 11 13 3 9 — 126
Campylobacteriosis 3,083 3,638 4,134 5,728 5,245 6,219 8,323 6,396 6,129 7,023 4,887 5,808 — 66,613
Candida auris, clinical † 95 78 69 65 48 67 66 85 89 105 96 138 — 1,001
Carbapenemase-producing carbapenem-resistant Enterobacteriaceae 143 211 218 240 211 197 247 249 249 313 234 306 — 2,818
Chancroid — — — — — — — 1 — — — — — 1
Chlamydia trachomatis infection § 115,433 128,956 132,998 165,538 129,892 122,547 159,369 134,272 129,342 162,433 118,726 150,078 — 1,649,584
Cholera — 1 — 4 1 2 2 — — 1 1 — — 12
Coccidioidomycosis 1,473 1,307 1,148 1,701 1,613 1,404 2,039 1,260 1,321 1,437 1,293 1,616 — 17,612
Coronavirus Disease 2019 (COVID-19)
Total 18,537,709 3,374,286 764,989 1,386,788 2,807,834 2,963,968 4,051,734 2,827,843 1,663,122 1,299,123 1,238,476 2,202,006 14,917 43,132,795
Confirmed 15,242,207 2,639,104 592,059 1,147,267 2,280,462 2,346,849 3,139,250 2,112,462 1,233,301 984,486 935,847 1,615,898 8,212 34,277,404
Probable  3,295,502 735,182 172,930 239,521 527,372 617,119 912,484 715,381 429,821 314,637 302,629 586,108 6,705 8,855,391
Cryptosporidiosis
Total 535 623 749 1,100 906 989 1,521 1,463 1,440 1,383 871 1,026 — 12,606
Confirmed 407 488 611 868 738 801 1,240 1,209 1,176 1,122 691 818 — 10,169
Probable 128 135 138 232 168 188 281 254 264 261 180 208 — 2,437
Cyclosporiasis 7 9 12 26 151 484 1,288 675 162 121 102 54 — 3,091
Dengue virus infections **
Dengue 35 14 19 22 30 35 136 264 302 310 132 155 — 1,454
Dengue-like illness — — — 2 — — 1 10 6 5 4 5 — 33
Severe dengue — — — 1 — 1 2 8 15 6 5 5 — 43
Diphtheria — — — — — — — — — — 1 — — 1
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 19 13 42 293 603 1,420 1,377 461 259 364 526 274 — 5,651
Ehrlichia chaffeensis infection 4 5 11 60 162 345 449 203 137 96 36 61 — 1,569
Ehrlichia ewingii infection — — — — — 8 12 3 1 — 1 — — 25
Undetermined ehrlichiosis/anaplasmosis — — 2 6 6 23 33 9 5 2 6 3 — 95
Giardiasis 765 987 941 1,213 977 994 1,388 1,327 1,396 1,496 1,170 1,165 — 13,819
Gonorrhea 49,634 51,235 51,553 63,934 50,712 49,956 64,437 51,753 50,167 61,971 45,306 57,352 — 648,010
Haemophilus influenzae, invasive disease
All ages, all serotypes 342 270 290 416 389 428 447 351 364 545 550 944 — 5,336
Age <5 years
Serotype b — 1 — 2 — — 3 3 2 3 3 — — 17
Non-b serotype 11 7 15 17 15 8 13 9 7 17 11 10 — 140
Nontypeable 13 9 6 22 13 20 22 14 19 42 31 43 — 254
Unknown serotype 19 17 11 22 15 31 27 14 19 33 33 32 — 273
Hansen's disease 5 2 7 10 4 5 5 1 3 6 4 10 — 62
Hantavirus infection, non-hantavirus pulmonary syndrome †† — — — — — — — — — — — — — —
Hantavirus pulmonary syndrome — — — 2 1 2 1 — 1 1 2 1 — 11
Hemolytic uremic syndrome post-diarrheal 9 11 12 26 19 28 42 54 30 30 20 31 — 312
Hepatitis, Viral Disease §§
Hepatitis A 233 243 235 298 212 183 206 136 147 140 119 112 — 2,264
Hepatitis B
Acute 113 172 165 237 168 166 224 133 176 200 127 245 — 2,126
Perinatal infection — 1 1 3 2 — 1 1 — — 1 3 — 13
Hepatitis C
Acute 350 424 536 633 447 431 471 457 418 508 360 593 — 5,628
Confirmed 303 362 446 541 394 370 403 407 362 441 307 512 — 4,848
Probable 47 62 90 92 53 61 68 50 56 67 53 81 — 780
Perinatal infection 10 15 18 17 14 23 30 13 15 22 9 11 — 197
Human immunodeficiency virus diagnoses 2,724 2,827 3,461 3,072 3,163 3,278 3,199 3,672 3,320 3,038 2,993 2,888 28 37,663
Influenza-associated pediatric mortality 3 3 6 10 1 6 2 1 5 7 12 60 — 116
Invasive pneumococcal disease ¶¶
All ages 1,665 1,205 1,228 1,898 1,415 1,179 925 647 879 1,665 1,869 3,787 — 18,362
Confirmed 1,642 1,184 1,210 1,855 1,374 1,150 898 628 861 1,623 1,821 3,670 — 17,916
Probable 23 21 18 43 41 29 27 19 18 42 48 117 — 446
Age <5 years 71 47 70 100 99 73 66 50 67 153 126 195 — 1,117
Confirmed 71 45 69 97 98 70 64 49 65 147 123 180 — 1,078
Probable — 2 1 3 1 3 2 1 2 6 3 15 — 39
Legionellosis 376 307 351 437 501 823 961 807 951 852 536 610 — 7,512
Leptospirosis 3 2 1 4 2 4 8 11 3 13 3 8 — 62
Listeriosis ***
Total 55 65 45 80 78 74 126 116 96 109 66 53 — 963
Confirmed 53 55 39 77 74 72 116 111 90 104 63 48 — 902
Probable 2 10 6 3 4 2 10 5 6 5 3 5 — 61
Lyme disease †††
Total 2,244 2,494 2,440 3,565 3,924 7,808 13,658 8,448 5,263 5,110 3,568 3,906 — 62,428
Confirmed 55 69 58 99 129 419 574 249 152 117 75 70 — 2,066
Probable 2,189 2,425 2,382 3,466 3,795 7,389 13,084 8,199 5,111 4,993 3,493 3,836 — 60,362
Malaria 123 116 81 98 112 128 260 218 261 223 125 187 — 1,932
Measles §§§
Total — 3 — — 1 4 — 4 13 12 29 55 — 121
Indigenous — 1 — — — 1 — — 5 8 29 54 — 98
Imported — 2 — — 1 3 — 4 8 4 — 1 — 23
Meningococcal disease
All serogroups 25 29 23 26 26 21 23 17 21 33 29 39 — 312
Serogroups ACWY 14 19 9 15 16 12 8 10 10 15 17 23 — 168
Serogroup B 5 4 8 4 3 — 2 4 3 3 3 8 — 47
Other serogroups 1 1 2 1 2 — 1 — 4 3 3 2 — 20
Unknown serogroup 5 5 4 6 5 9 12 3 4 12 6 6 — 77
Mpox ¶¶¶ — — — — 28 517 7,688 11,099 6,249 2,788 950 502 — 29,821
Mumps 17 18 15 33 35 36 20 20 25 43 38 86 — 386
Novel Influenza A virus infections — 1 — 1 — — — 5 3 2 — — — 12
Pertussis 151 145 196 247 270 215 219 201 227 393 392 388 — 3,044
Plague **** — — — — — — — — — — — — — —
Poliomyelitis, paralytic — — — — — — — 1 — — — — — 1
Poliovirus infection, nonparalytic — — — — — — — — — — — — — —
Psittacosis — — — — 2 2 1 — — 1 — 1 — 7
Q fever
Total 8 16 26 31 14 11 18 17 17 16 8 12 — 194
Acute 8 16 25 27 13 9 17 13 16 11 8 8 — 171
Chronic — — 1 4 1 2 1 4 1 5 — 4 — 23
Rabies
Animal 165 161 243 295 348 369 348 486 428 287 243 182 3 3,558
Human — — — — — — — — — — — — — —
Rubella — — — 1 2 1 — — — 1 — 2 — 7
Rubella, congenital syndrome — — — — — — — — — — — — — —
Salmonella Paratyphi infection †††† 10 12 11 10 2 5 12 10 15 11 3 29 — 130
Salmonella Typhi infection §§§§ 31 27 47 44 26 31 44 57 58 31 18 28 — 442
Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) ¶¶¶¶ 2,016 1,954 2,391 3,845 3,859 4,740 7,772 6,833 7,323 7,067 4,011 4,318 — 56,129
Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — — —
Shiga toxin-producing Escherichia coli (STEC) 577 718 851 1,524 1,324 1,635 2,180 1,987 1,695 1,622 1,042 1,251 — 16,406
Shigellosis 767 874 950 1,279 1,062 1,112 1,565 1,420 1,370 1,768 1,170 1,407 — 14,744
Smallpox — — — — — — — — — — — — — —
Spotted fever rickettsiosis
Total 29 23 22 64 173 207 280 154 145 107 43 45 — 1,292
Confirmed — — — 1 8 10 16 2 7 — 2 1 — 47
Probable 29 23 22 63 165 197 264 152 138 107 41 44 — 1,245
Streptococcal toxic shock syndrome 9 26 15 21 21 24 19 15 14 38 24 107 — 333
Syphilis
Total, all stages ***** 14,438 15,955 16,506 20,482 16,025 15,326 20,317 17,470 16,623 20,478 14,869 18,734 — 207,223
Congenital ††††† 307 270 314 263 279 295 338 352 317 340 342 338 — 3,755
Primary and secondary 4,165 4,508 4,778 6,008 4,493 4,345 6,168 5,090 4,867 5,581 3,991 5,016 — 59,010
Tetanus — 2 2 1 3 5 2 3 1 3 3 1 — 26
Toxic shock syndrome (other than Streptococcal) 4 3 4 2 — 1 3 4 2 3 2 3 — 31
Trichinellosis — — — — — — 5 4 — — — — — 9
Tuberculosis 394 502 600 829 623 704 780 680 609 849 652 1,109 — 8,331
Tularemia — 4 7 6 22 28 34 18 8 16 6 18 — 167
Vancomycin-intermediate Staphylococcus aureus 1 4 8 8 9 7 10 5 8 10 6 6 — 82
Vancomycin-resistant Staphylococcus aureus §§§§§ — — — 1 1 — — — — — — — — 2
Varicella morbidity 270 272 356 516 390 293 314 289 347 445 374 482 — 4,348
Varicella mortality — — — — 1 — 1 — 1 — — — — 3
Vibriosis
Total 97 121 137 222 185 242 455 501 364 346 189 179 — 3,038
Confirmed 33 37 38 80 87 116 247 296 197 189 88 66 — 1,474
Probable 64 84 99 142 98 126 208 205 167 157 101 113 — 1,564
Viral hemorrhagic fevers
Chapare virus ¶¶¶¶¶ — — — — — — — — — — — — — —
Crimean-Congo hemorrhagic fever virus ****** — — — — — — — — — — — — — —
Ebola virus ****** — — — — — — — — — — — — — —
Guanarito virus ****** — — — — — — — — — — — — — —
Junin virus ****** — — — — — — — — — — — — — —
Lassa virus ****** — — — — — — — — — — — — — —
Lujo virus ****** — — — — — — — — — — — — — —
Machupo virus ****** — — — — — — — — — — — — — —
Marburg virus ****** — — — — — — — — — — — — — —
Sabia virus ****** — — — — — — — — — — — — — —
Yellow fever — — — — — — — — — — — — — —
Zika virus
Zika virus disease, congenital †††††† — — — — — — 1 — — — — — — 1
Zika virus disease, non-congenital 1 — 1 — — 2 1 — — — — — — 5
Zika virus infection, congenital †††††† — — — — — — — — — — — — — —
Zika virus infection, non-congenital — — 1 — — — 1 — — — — — — 2
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • NC: Not Calculated — There is insufficient data available to support this statistic.
  • * Month is defined using MMWR week (https://ndc.services.cdc.gov/wp-content/uploads/2021/02/MMWR_Week_overview.pdf). MMWR week calendars can be found at https://ndc.services.cdc.gov/event-codes-other-surveillance-resources/.
  • † Note that Candida auris colonization/screening cases are not included in this table. Additionally, there may be case count discrepancies of Candida auris clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for Candida auris case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.
  • § Beginning in January 2022, only confirmed cases are published to align with the approved CSTE position statement 21-ID-06, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years.
  • ¶ Of the reporting areas that submitted 2022 aggregate COVID-19 data to CDC, three did not submit probable cases. American Samoa, New York (excluding New York City), and U.S. Virgin Islands did not collect probable cases.
  • ** Counts include confirmed and probable dengue cases.
  • †† Case counts may include Old World hantavirus infections, such as Seoul virus.
  • §§ Chronic hepatitis B and chronic hepatitis C data are not included in NNDSS tables but reported case counts are included in the annual Viral Hepatitis Surveillance Report, 2022, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • ¶¶ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • *** Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately.
  • ††† For surveillance reporting purposes, jurisdictions are grouped into high- and low-incidence categories. Confirmed cases are only reported from low-incidence jurisdictions; however, probable cases are reported from both high- and low-incidence jurisdictions. For more information on jurisdiction classifications, visit https://www.cdc.gov/lyme. Currently, high-incidence jurisdictions include Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York (excluding New York City), New York City, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, Wisconsin, and the District of Columbia.
  • §§§ Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
  • ¶¶¶ CSTE adopted Mpox as a nationally notifiable condition on June 23, 2022 and beginning August 1, 2022 confirmed and probable cases are published to align with the CSTE position statement 22-ID-10. Case classifications for cases reported prior to August 1, 2022 should not have been retroactively changed based on the case definition in the CSTE position statement 22-ID-10.
  • **** Beginning in 2020, confirmed and probable plague cases began to be combined and published.
  • †††† Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • §§§§ Beginning in January 2019, cases began to be reported as Salmonella Typhi infection. In previous years, cases were reported as typhoid fever.
  • ¶¶¶¶ Beginning in January 2019, cases began to be reported as salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • ***** Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations) and congenital syphilis.
  • ††††† Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth.
  • §§§§§ Vancomycin-resistant Staphylococcus aureus cases reported in this table may not have been verified by CDC. CDC verified 0 vancomycin-resistant Staphylococcus aureus cases in 2022.
  • ¶¶¶¶¶ Beginning in January 2022, Chapare virus was added as a nationally notifiable condition, and confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04.
  • ****** Beginning in January 2022, confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04, whereas in previous years, only confirmed cases were published.
  • †††††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2022 annual tables were officially closed on March 29, 2024.
  2. The list of national notifiable Infectious diseases and conditions for 2022 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2022" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2022 data are available at https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2022 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2022, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2022" population estimates for years 2020-2022 were released March 2024 by the National Cancer Institute at https://seer.cancer.gov/popdata/. For more information, see https://seer.cancer.gov/popdata/singleages.html Population estimates for territories are the 2022 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on May 02, 2024, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Genre" box on the left-hand side and select "Annual Reports".
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction is ≤24 months)
    • Perinatal hepatitis C infection (age restriction is ≤36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2022 (National Center for Health Statistics Natality 2022, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. Disease data presented in the 2022 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.